TUSTIN, Calif., Jan. 30 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc., (JPI) is an international biopharma company that, together with JPI, engages in the development, manufacture and marketing of proprietary pharmaceutical, health care and diagnostic products. The Company announced today that JPI's subsidiary, JJB, won a supply contract for the delivery of Domperidone to the Chinese Military through HaiHong Pharmaceutical E-Commerce Account Settlement Service Ltd., the Chinese agents for the Chinese Military Planned Drugs Online Focused Purchase Campaign.
Frank Zheng, Managing Director of JPI, stated that "this distribution agreement will position JJB to become the premier supplier for the Military Strategic Drug Reserve. It is estimated that Domperidone could realize sales of approximately $6.6 million in 2008 through this individual contract. JPI is also promoting other JJB and YYB products through this supply channel and is confident that additional products from JJB and YYB will also win bids."
Mr. Gary Dreher, CEO of AMDL noted that "this new distribution channel illustrates JPI's ability to execute on its 2008 business plan and significantly improves JPI's ability to grow its sales in 2008 and beyond."
About Domperidone: Domperidone is an important medicine for treating nausea and vomiting. JPI's generic version of this product is significantly lower priced than other China pharma competitors.
About Jade Pharmaceutical Inc.: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those projected
in such forward-looking statements. The Company cautions readers not to
place undue reliance on any forward-looking statements. The Company does
not undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or unanticipated events
as they occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved